Claims
- 1. A compound of Formula I, including pharmaceutically acceptable salts thereof,
- 2. A compound of claim 1, wherein:
R15, R16, R17, R18, R19, R20, R21, R22 are each independently H or methyl; wherein only one or zero of R15, R16, R17, R18, R19, R20, R21 and R22 is methyl; Y is O; and Q is a member selected from groups (A) and (B) consisting of 111provided R3 and R4 are each hydrogen; and R5 is selected from the group consisting of halogen, cyano, methoxy, COOR8, C(O)NHCH3, C(O)NHheteroaryl, and heteroaryl; and 112provided R3 is hydrogen; R4 is selected from the group consisting of hydrogen, halogen, methoxy, cyano, COOR8, C(O)NHCH3, C(O)NHheteroaryl and heteroaryl; and R6does not exist.
- 3. A compound of claim 2 wherein R13 and R14 are independently selected from the group consisting of hydrogen, (C1-6)alkyl and phenyl; or taken together with the nitrogen atom to which they are attached forms a pyrrolidinyl or morpholinyl ring.
- 4. A compound of claim 3 in which Q is a member selected from groups (A) and (B) consisting of
- 5. A compound of claim 4 wherein:
R13 and R14 are each methyl.
- 6. A compound of claim 4 wherein:
R13 and R14 taken together with the nitrogen atom to which they are attached form a morpholinyl ring.
- 7. A compound of claim 5 wherein:
Q is 115and R5 is selected from the group consisting of methoxy, C(O)NHCH3, and heteroaryl.
- 8. A compound of claim 6 wherein:
Q is 116and R5 is selected from the group consisting of C(O)NHCH3 and heteroaryl.
- 9. A compound of claim 5 wherein:
Q is 117R4 is selected from the group consisting of C(O)NHCH3 and heteroaryl; and heteroaryl is oxadiazolyl, triazolyl, pyrazolyl, thiazolyl, pyrazinyl or oxazolyl.
- 10. A compound of claim 6 wherein:
Q is 118R4 is selected from the group consisting of C(O)NHCH3 and heteroaryl; and heteroaryl is oxadiazolyl, triazolyl, pyrazolyl, thiazolyl, pyrazinyl or oxazolyl.
- 11. A pharmaceutical composition which comprises an antiviral effective amount of a compound of Formula I, including pharmaceutically acceptable salts thereof, as claimed in claim 1, and one or more pharmaceutically acceptable carriers, excipients or diluents.
- 12. The pharmaceutical composition of claim 11, useful for treating infection by HIV, which additionally comprises an antiviral effective amount of an AIDS treatment agent selected from the group consisting of:
(a) an AIDS antiviral agent; (b) an anti-infective agent; (c) an immunomodulator; and (d) HIV entry inhibitors.
- 13. A method for treating a mammal infected with the HIV virus comprising administering to said mammal an antiviral effective amount of a compound of Formula I, including pharmaceutically accceptable salts thereof, as claimed in claim 1, and one or more pharmaceutically acceptable carriers, excipients or diluents.
- 14. The method of claim 13, comprising administering to said mammal an antiviral effective amount of a compound of Formula I, including pharmaceutically acceptable salts thereof, in combination with an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: an AIDS antiviral agent; an anti-infective agent; an immunomodulator; and an HIV entry inhibitor.
REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application Serial No. 60/398,812 filed Jul. 25, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60398812 |
Jul 2002 |
US |